Lance Baldo's most recent trade in Adaptive Biotechnologies Corp was a trade of 3,350 Common Stock done at an average price of $11.4 . Disclosure was reported to the exchange on March 8, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.43 per share. | 08 Mar 2022 | 3,350 | 17,171 (0%) | 0% | 11.4 | 38,291 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 07 Mar 2022 | 2,373 | 20,521 (0%) | 0% | 12.0 | 28,500 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 57,234 | 57,234 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 22,894 | 22,894 (0%) | 0% | 0 | Common Stock | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 40,000 | 341,250 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 27 Jan 2021 | 40,000 | 40,000 (0%) | 0% | 7.8 | 312,000 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 58.22 per share. | 27 Jan 2021 | 17,499 | 22,501 (0%) | 0% | 58.2 | 1,018,792 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 59.24 per share. | 27 Jan 2021 | 14,233 | 8,268 (0%) | 0% | 59.2 | 843,163 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 60.01 per share. | 27 Jan 2021 | 8,268 | 0 (0%) | 0% | 60.0 | 496,163 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2020 | 6,250 | 381,250 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 07 Dec 2020 | 6,250 | 6,250 (0%) | 0% | 7.8 | 48,750 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.14 per share. | 07 Dec 2020 | 3,000 | 2,470 (0%) | 0% | 50.1 | 150,420 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 51.26 per share. | 07 Dec 2020 | 2,470 | 0 (0%) | 0% | 51.3 | 126,612 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.79 per share. | 07 Dec 2020 | 780 | 5,470 (0%) | 0% | 48.8 | 38,056 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2020 | 6,250 | 387,500 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 06 Nov 2020 | 6,250 | 6,250 (0%) | 0% | 7.8 | 48,750 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.54 per share. | 06 Nov 2020 | 5,453 | 797 (0%) | 0% | 50.5 | 275,595 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 51.26 per share. | 06 Nov 2020 | 797 | 0 (0%) | 0% | 51.3 | 40,854 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 06 Oct 2020 | 6,250 | 6,250 (0%) | 0% | 7.8 | 48,750 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2020 | 6,250 | 393,750 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 48.90 per share. | 06 Oct 2020 | 4,236 | 2,014 (0%) | 0% | 48.9 | 207,140 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 49.84 per share. | 06 Oct 2020 | 2,014 | 0 (0%) | 0% | 49.8 | 100,378 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 29 Sep 2020 | 25,000 | 25,000 (0%) | 0% | 7.8 | 195,000 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2020 | 25,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 50.00 per share. | 29 Sep 2020 | 25,000 | 0 (0%) | 0% | 50 | 1,250,000 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2020 | 4,149 | 425,000 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Sep 2020 | 4,149 | 0 (0%) | 0% | 40 | 165,960 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 10 Sep 2020 | 4,149 | 4,149 (0%) | 0% | 7.8 | 32,362 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.78 per share. | 10 Sep 2020 | 18 | 18 (0%) | 0% | 7.8 | 140 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2020 | 18 | 429,149 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Sep 2020 | 18 | 0 (0%) | 0% | 40 | 720 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 08 Sep 2020 | 2,083 | 2,083 (0%) | 0% | 7.8 | 16,247 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Sep 2020 | 2,083 | 429,167 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.17 per share. | 08 Sep 2020 | 2,083 | 0 (0%) | 0% | 36.2 | 75,342 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 7.80 per share. | 06 Aug 2020 | 6,250 | 6,250 (0%) | 0% | 7.8 | 48,750 | Common Stock |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2020 | 6,250 | 431,250 | - | - | Stock Option (Right to Buy) | |
| Adaptive Biotechnologies Corp | Lance Baldo | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 06 Aug 2020 | 6,250 | 0 (0%) | 0% | 40 | 250,000 | Common Stock |